Enhancement in CD8+ T cell infiltration and effector function, along with the synergistic augmentation of αPD-1 therapy, highlights the potential clinical significance of GB2 in CRC immunotherapy. This evidence concerns the gene GABBR2 and colorectal carcinoma.